SCHEMBL15720873

SCHEMBL15720873

COCCOCCOCCN(C)c1cc(OC)cc([N+](=O)[O-])c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
LMNA P02545 5/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.36
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX5 P09917 1/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
RAB9A P51151 1/20 0.33
CDC25C P30307 1/20 0.33
THRB P10828 1/20 0.33
APEX1 P27695 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29833260 0.92 CHRNB2 (0.42) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL15720914 0.79 CHRNB2 (0.43) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL16106495 0.78 ALDH1A1 (0.49) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL16106244 0.78 ALDH1A1 (0.49) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL16150299 0.78 ALDH1A1 (0.49) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL15720893 0.77 ALDH1A1 (0.35) ALDH1A1
SCHEMBL15720161 0.76 CHRNB2 (0.56) CHRNB2CHRNA4LMNAALDH1A1MAPT
SCHEMBL3924064 0.76 LMNA (0.46) CHRNB2CHRNA4LMNAMAPTPTGS1
SCHEMBL15720832 0.74 MAPT (0.45) LMNAALDH1A1MAPTPTGS1PTGS2
SCHEMBL15721055 0.72 MEN1 (0.41) LMNAALDH1A1MAPTPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732063-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-08-15 US disclosed
EP-2925742-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2016-10-26 EP disclosed
US-20150329523-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2015-11-19 US disclosed
EP-2925742-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-10-07 EP disclosed
WO-2014076484-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329523-A1 KINASE INHIBITORS SYK, SRC, BTK CHRNB2 2178/4885CHRNA4 3163/4885LMNA 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.